What comes as a piece of information researchers have discovered an anti-parasitic drug that’s already accessible globally can kill COVID-19 grown cell cultures within two days. Released in journal Antiviral Research, the study implies that the drug ivermectin’ stopped the virus SARS-Cov-2 from growing in cell culture within two days. The most recent advancement may cause trial and the development of a new clinical treatment for the pandemic.
“We found that even a single dose could essentially get rid of all viral RNA by 48 hours and that even at 24 hours there was a very significant reduction inside,” PTI quoted research co-author Kylie Wagstaff, Monash University in Australia as stating.
The anti-parasitic drug can kill COVID-19 in 24 hours
The scientists also added that Ivermectin is an approved anti-parasitic medication that has proved to be effective in vitro against a wide selection of viruses such as Influenza, HIV, Dengue and Zika Virus.
But, Wagstaff has cautioned that trials are required to be performed on patients and that tests conducted in the analysis were in vitro.
“Ivermectin is very widely used and seen as a safe medication. We need to figure out today if the dose you are able to use it at in people will be successful – that is the next step,” Wagstaff told PTI.
“Sometimes when we are having a global pandemic and there’s not an accepted treatment, if we had a compound which has been already available around the globe then that might help people sooner,” she added.
Though the mechanism of Ivermectin on the virus remains to be known, scientists say it works to stop the virus’ dampening down’ the host cells’ ability.
“As the virologist who had been part of the team who were first to isolate and discuss SARS-COV2 out China at January 2020, I am excited about the prospect of Ivermectin used as a potential drug against COVID-19,” PTI quoted Leon Caly, research co-author in the Royal Melbourne Hospital in Australia as saying.
The scientists warned that the use of Ivermectin to combat COVID-19 would rely on results of prospective testing and ultimately clinical trials.